Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 28

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 28
---
 company. Our growth strategy We are driving and leading a paradigm shift within precision diagnostics. Our vision is to leverage our novel smNGS platform to develop ultrasensitive diagnostic tests that enable personalized solutions and enhance patient outcomes. Our growth strategy to achieve this goal includes the following elements:

| • |     | Drive increased adoption of our existing products in the prenatal and oncology markets. |

| • |     | Build beyond our extensive library of clinical evidence to support favorable coverage and reimbursement. |

| • |     | Utilize our smNGS platform and R&D capabilities to efficiently expand and improve our portfolio of category-defining 
 molecular diagnostic tests.                                                                                          |

| • |     | Continue to deploy AI across our entire organization, including laboratory operations, to improve efficiency and 
 productivity.                                                                                                    |

| • |     | Leverage our growing clinical dataset with AI to improve the utility of diagnostics and enable personalized medicine. |

Recent developments Preliminary unaudited operating results We are in the process of finalizing our operating results as of and for the three months ended September 30, 2025. We have presented below certain preliminary operating results representing our estimates for the three months ended September 30, 2025. Actual results remain subject to the completion of our financial close processes. These preliminary estimates are based on currently available information and do not present all information necessary for an understanding of our operating results as of and for the three months ended September 30, 2025. The preliminary estimates included in this prospectus have been prepared by and are the responsibility of our management. Our independent registered public accounting firm has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary estimates included below and does not express an opinion or any other form of assurance with respect thereto.

10

We expect to complete the preparation of our interim consolidated financial statements as of and for the three months ended September 30, 2025 following the completion of this offering. Although we are currently unaware of any items that would require us to make adjustments to the information set forth below, it is possible that we or our independent registered public accounting firm may identify such items as we complete the preparation of our interim consolidated financial statements and any resulting changes could be material. Factors that could cause the preliminary information to differ include, but are not limited to: additional adjustments arising from discovery of new information that affects accounting estimates; management judgment; or impacts of valuation methodologies underlying these estimated results. Accordingly, undue reliance should not be placed on these